Combigan is a drug owned by Abbvie Inc. It is protected by 11 US drug patents filed from 2013 to 2018 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 19, 2023. Details of Combigan's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7323463 | Combination of brimonidine and timolol for topical ophthalmic use |
Jan, 2023
(1 year, 11 months ago) |
Expired
|
| US9907801 | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) |
Expired
|
| US9907802 | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) |
Expired
|
| US7642258 | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) |
Expired
|
| US8133890 | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) |
Expired
|
| US8354409 | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) |
Expired
|
| US8748425 | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) |
Expired
|
| US9474751 | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) |
Expired
|
| US7030149 | Combination of brimonidine timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) |
Expired
|
| US9770453 | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) |
Expired
|
| US7320976 | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Combigan's patents.
Latest Legal Activities on Combigan's Patents
Given below is the list of recent legal activities going on the following patents of Combigan.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 15 Apr, 2024 | US8133890 (Litigated) |
| Maintenance Fee Reminder Mailed Critical | 30 Oct, 2023 | US8133890 (Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 07 Sep, 2021 | US9907802 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 07 Sep, 2021 | US9907801 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 06 Jul, 2021 | US7642258 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 26 Mar, 2021 | US9770453 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 Sep, 2019 | US8133890 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 29 Jul, 2019 | US7323463 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 22 Jul, 2019 | US7320976 |
| Email Notification Critical | 09 Mar, 2018 | US9907801 |
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Combigan and ongoing litigations to help you estimate the early arrival of Combigan generic.
Combigan's Litigations
Combigan been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Mar 09, 2015, against patent number US7030149. The petitioner Ferrum Ferro Capital, LLC, challenged the validity of this patent, with Allergan Sales, LLC as the respondent. Click below to track the latest information on how companies are challenging Combigan's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US7030149 | March, 2015 |
Terminated-Denied
(21 Sep, 2015) | Allergan Sales, LLC | Ferrum Ferro Capital, LLC |
Several oppositions have been filed on Combigan's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Combigan's generic, the next section provides detailed information on ongoing and past EP oppositions related to Combigan patents.
Combigan's Oppositions Filed in EPO
Combigan has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 04, 2013, by Stada Arzneimittel Ag. This opposition was filed on patent number EP03726234A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP03726234A | Oct, 2013 | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi | Revoked |
| EP03726234A | Oct, 2013 | Hexal AG | Revoked |
| EP03726234A | Oct, 2013 | Generics [UK] Limited | Revoked |
| EP03726234A | Oct, 2013 | Alfred E. Tiefenbacher GmbH & Co. KG | Revoked |
| EP03726234A | Oct, 2013 | Teva Pharmaceutical Industries LTD. | Revoked |
| EP03726234A | Oct, 2013 | STADA Arzneimittel AG | Revoked |
US patents provide insights into the exclusivity only within the United States, but Combigan is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Combigan's family patents as well as insights into ongoing legal events on those patents.
Combigan's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Combigan's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 19, 2023 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Combigan Generic API suppliers:
Brimonidine Tartrate; Timolol Maleate is the generic name for the brand Combigan. 8 different companies have already filed for the generic of Combigan, with Alembic having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Combigan's generic
How can I launch a generic of Combigan before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Combigan's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Combigan's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Combigan -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 0.2%/0.5% | 21 Nov, 2008 | 1 | 19 Apr, 2022 | Extinguished |
Alternative Brands for Combigan
Combigan which is used for lowering elevated intraocular pressure in patients with glaucoma or ocular hypertension., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
About Combigan
Combigan is a drug owned by Abbvie Inc. It is used for lowering elevated intraocular pressure in patients with glaucoma or ocular hypertension. Combigan uses Brimonidine Tartrate; Timolol Maleate as an active ingredient. Combigan was launched by Abbvie in 2007.
Approval Date:
Combigan was approved by FDA for market use on 30 October, 2007.
Active Ingredient:
Combigan uses Brimonidine Tartrate; Timolol Maleate as the active ingredient. Check out other Drugs and Companies using Brimonidine Tartrate; Timolol Maleate ingredient
Treatment:
Combigan is used for lowering elevated intraocular pressure in patients with glaucoma or ocular hypertension.
Dosage:
Combigan is available in solution/drops form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.2%;EQ 0.5% BASE | SOLUTION/DROPS | Prescription | OPHTHALMIC |